Daily Respiratory Research Analysis
Analyzed 222 papers and selected 3 impactful papers.
Summary
Analyzed 222 papers and selected 3 impactful articles.
Selected Articles
1. Extended use of point-of-care technology by acute community nurses during in-home assessment of older adults with potential acute respiratory conditions: a parallel-group, open-label, randomised controlled trial.
In a pragmatic, open-label RCT of 623 older adults assessed at home by community nurses, extended POCT including focused lung ultrasound did not reduce 30-day admissions but significantly lowered 30-day mortality (RR 0.44). No intervention-related harms were reported.
Impact: This trial provides high-quality, real-world evidence on the value of deploying advanced diagnostics (including lung ultrasound) in community-based acute respiratory care, revealing a mortality benefit despite unchanged admission rates.
Clinical Implications: Extended POCT and lung ultrasound may improve survival in older adults evaluated at home, but may not change admission decisions. Programs should emphasize clinical decision support, standardized pathways, and targeted use in subgroups most likely to benefit.
Key Findings
- No reduction in 30-day hospital admissions: 38% (usual care) vs 40% (intervention), RR 1.06 (95% CI 0.86–1.30).
- Lower 30-day mortality with extended POCT: 8% vs 4%, RR 0.44 (95% CI 0.22–0.88).
- No intervention-related harms; analyses performed by intention-to-treat; NCT05546073.
Methodological Strengths
- Randomised, stratified, intention-to-treat pragmatic design in real-world primary care.
- Pre-specified outcomes with registered protocol; inclusion of focused lung ultrasound and tele-ultrasound.
Limitations
- Open-label design may influence clinical decisions and downstream care.
- The trial may be underpowered for mortality as a safety outcome; single-country setting limits generalizability.
Future Directions: Define decision algorithms that integrate POCT and lung ultrasound findings, identify subgroups with maximal benefit, and assess cost-effectiveness and patient-reported outcomes.
BACKGROUND: Diagnosing acute respiratory conditions in adults older than 65 years is challenging due to age-related physiological changes, which increase diagnostic complexity and the risk of hospital admission. We investigated whether extended point-of-care technology (POCT), used at home by acute community nurses, reduced hospital admissions in older adults. METHODS: In this parallel-group, open-label, randomised controlled trial, conducted in a primary care setting in Denmark, adults aged 65 years and older with potential respiratory symptoms were randomly assigned (1:1) using computer-generated allocation, with blocked randomisation (variable block sizes of two, four, and six) stratified by gender, to standard nurse-led care (clinical assessment, vital signs, and C-reactive protein and haemoglobin) or standard nurse-led care with extended POCT (additional blood tests, focused lung ultrasound, and tele-ultrasound). Participants and clinicians were not masked to assignment. The primary outcome was hospital admission within 30 days. Mortality was assessed as a prespecified safety outcome. Analyses were done on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, NCT05546073. FINDINGS: Between Oct 14, 2022, and Nov 18, 2023, 623 participants were randomly assigned. 313 (50%) of 623 participants were assigned usual care and 310 (50%) were assigned the intervention. No difference was observed in hospital admissions within 30 days (112 [38%] participants in the usual care group vs 119 [40%] participants in the intervention group; risk ratio [RR] 1·06, 95% CI 0·86-1·30). 30-day mortality was lower in the intervention group (25 [8%] deaths in the usual care group vs 11 [4%] deaths in the intervention group; RR 0·44, 95% CI 0·22-0·88). No intervention-related harms were observed. INTERPRETATION: Compared with standard nurse-led community care including basic POCT, extended POCT did not reduce hospital admissions among older adults with potential acute respiratory conditions. These findings suggest that the added value of extended diagnostic technology in community-based acute care might have little impact on admission decisions and warrant further evaluation focusing on clinical decision making and patient trajectories. FUNDING: Region of Southern Denmark, Karen Elise Jensen Foundation, AP Moeller Foundation, Hartmann Foundation, Gangsted Foundation, and Odense University Hospital Innovation Foundation.
2. Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis.
Across 33 studies, GLP1 receptor agonists most effectively reduced CRD exacerbations in T2D, with SGLT2 inhibitors second. Thiazolidinediones were associated with reduced incident CRD, and antidiabetic drugs (especially metformin) lowered mortality; MR supported a link between GLP1R activation and lower asthma risk.
Impact: By integrating NMA with genetic causal inference, this study informs antidiabetic drug selection to mitigate respiratory risks in multimorbid T2D populations.
Clinical Implications: In T2D patients with comorbid or high risk of CRD, prioritize GLP1RAs (and consider SGLT2is) to reduce exacerbations; metformin remains valuable for mortality reduction. Tailor choices to respiratory phenotypes and cardiovascular profiles.
Key Findings
- GLP1 receptor agonists ranked highest for reducing CRD exacerbations; SGLT2 inhibitors ranked second.
- Thiazolidinediones were associated with reduced incident chronic respiratory disease.
- Antidiabetic drugs decreased mortality in T2D with CRD, especially metformin; MR linked GLP1R activation to lower asthma risk.
- Registered with PROSPERO (CRD42024542379).
Methodological Strengths
- Combination of conventional meta-analysis, network meta-analysis, and two-sample Mendelian randomization.
- Comparison across nine antidiabetic classes with multiple respiratory outcomes; protocol registered.
Limitations
- Heterogeneity and residual confounding across included studies; indirect comparisons inherent to NMA.
- Genetic instruments may have pleiotropy; clinical endpoints and definitions vary between studies.
Future Directions: Head-to-head RCTs in T2D with defined respiratory phenotypes and mechanistic work to explain GLP1RA/SGLT2i respiratory benefits.
BACKGROUND: Multimorbidity management is crucial in aging populations, particularly for chronic respiratory diseases (CRDs) and diabetes. Their coexistence increases exacerbation and mortality risks. Antidiabetic drugs may differentially impact respiratory outcomes. OBJECTIVES: To evaluate the effects of antidiabetic drugs on CRDs in individuals with type 2 diabetes (T2D). DESIGN: Systematic review with conventional and network meta-analyses (NMAs). DATA SOURCES AND METHODS: We conducted a systematic review with conventional meta-analysis, NMA for drug comparisons, and two-sample Mendelian randomization for genetic evidence. We assessed nine antidiabetic drug classes for associations with CRD exacerbations, incidence, and all-cause mortality in individuals with T2D. RESULTS: Our analysis of 33 studies ( CONCLUSION: GLP1RAs provide the strongest protection against CRD exacerbations in T2D patients, with SGLT2is as the second-most effective option. These findings highlight the potential for personalized antidiabetic therapy in multimorbidity management. Further studies should validate these findings and elucidate underlying mechanisms. TRIAL REGISTRATION: PROSPERO (ID: CRD42024542379). Antidiabetic drug and chronic respiratory disease Our study revealed GLP1RAs as most protective against respiratory exacerbation. Thiazolidinediones reduced incident chronic respiratory disease in T2D. Antidiabetic drugs decreased mortality in individuals with comorbid T2D and chronic respiratory disease, specially metformin. Genetic evidence linked GLP1R activation to lower asthma risk.
3. Long-term exposure to air pollution and risk of adult-onset asthma and COPD: Danish nationwide cohort study.
In a nationwide cohort of 3.2 million adults with >50 million person-years, interquartile-range increases in NO2 and black carbon were consistently associated with higher risks of adult-onset asthma and COPD, while PM2.5 associations attenuated after co-pollutant adjustment. Findings implicate combustion-related pollutants as key drivers and support targeted emission-control policies.
Impact: This is one of the largest population-based analyses disentangling pollutant-specific risks, highlighting black carbon and NO2 as robust predictors beyond PM2.5. It provides actionable evidence for air quality policy to prevent chronic respiratory diseases.
Clinical Implications: Clinicians should counsel high-risk adults on exposure reduction, and policymakers should prioritize reducing combustion-related emissions (traffic, residential heating). Consider incorporating BC and NO2 metrics into risk assessments and public health standards.
Key Findings
- Interquartile-range increases in NO2 and black carbon were associated with higher asthma incidence (HR 1.16 and 1.17) and COPD incidence (HR 1.05 and 1.06).
- PM2.5 associations attenuated to null after adjustment for NO2/BC, whereas NO2/BC associations remained robust after adjusting for PM2.5.
- Over 50 million person-years with 52,648 incident asthma and 146,269 COPD cases provided strong statistical power.
Methodological Strengths
- Nationwide cohort of 3.2 million adults with >50 million person-years and extensive confounder adjustment (smoking, BMI, socioeconomic factors).
- Exposure estimated by European hybrid land-use regression with co-pollutant models to separate pollutant-specific effects.
Limitations
- Incident events based on first hospital contact may miss primary-care diagnoses.
- Exposure misclassification possible due to residential modeling; residual confounding cannot be excluded.
Future Directions: Assess causal pathways (e.g., oxidative stress, airway remodeling), evaluate impacts of targeted emission-control policies on incident disease, and refine personal exposure assessments (wearables, microenvironments).
RATIONALE: Long-term exposure to air pollution contributes to chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). While the effect of fine particulate matter (PM2.5) and nitrogen dioxide (NO2) are supported by evidence, the contribution of black carbon (BC), a combustion-related pollutant, remains unclear. OBJECTIVES: To investigate associations of long-term exposure to BC as well as PM2.5 and NO2 with incidence of adult-onset asthma and COPD in Denmark. METHODS: We followed 3.2 million Danish residents aged 30 years or older on January 1, 2000 until December 31, 2018, for incidence of asthma and COPD (first hospital contact), and combined incidence [first prescription for obstructive airway disease (OAD) medication]. Annual mean concentrations of air pollutants were estimated using European-wide hybrid land-use regression models. Cox proportional hazard models were used with adjustment of demographic, socioeconomic factors, smoking, and body mass index. RESULTS: During 50.7, 50.4, and 44.4 million person-years of follow-up, 52,648 participants developed asthma, 146,269 developed COPD, and 393,211 were prescribed OAD medication, respectively. An interquartile range increase of 2.0 and 10.3 µg/m3, and 0.5 × 10-5/m in PM2.5, NO2, and BC, respectively, were associated with higher risks of asthma incidence [hazard ratio: 1.10 (95% confidence interval: 1.08, 1.13); 1.16 (1.13, 1.19); 1.17 (1.14, 1.20)], COPD incidence [1.04 (1.02, 1.05); 1.05 (1.03, 1.07); 1.06 (1.04, 1.08)], and OAD medication [1.02, (1.01, 1.03); 1.05 (1.03, 1.06); 1.03 (1.02, 1.05)]. The observed association with PM2.5 were attenuated or became null after adjusting for NO2 or BC, while those with NO2 or BC remained robust after adjusting for PM2.5. CONCLUSION: In a large Danish nationwide analysis, air pollution is an important predictor for adult-onset asthma and COPD. Our findings suggest that the relevance of pollutants originating from combustion sources, as reflected by the association with BC and NO2, may contribute importantly to these respiratory outcomes. Targeted actions to reduce combustion-related emissions, including those leading to BC formation, may further help decrease the burden of chronic respiratory diseases.